Tech Company Financing Transactions
Progyny Funding Round
On 5/3/2017, Progyny secured $10 million in Series B investment from Kleiner Perkins Caufield & Byers, SR One Capital Management and TPG Biotech.
Transaction Overview
Company Name
Announced On
5/3/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
Kleiner Perkins Caufield & Byers (Lead Investor) (Beth Seidenberg)
Proceeds Purpose
This new round of financing will be used to continue to grow the customer base and Progyny's leading national network of high-quality fertility specialists, as well as the infrastructure and systems needed to support its revenue growth.
Company Information
Company Status
Publicly-held
Industry
Healthcare Services
Mailing Address
99 Hudson St. 7th Floor
New York, NY 10013
USA
New York, NY 10013
USA
Phone
Website
Email Address
Overview
Progyny (Nasdaq: PGNY) is the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Schlanger
Chief Financial Officer
Mark Livingston
Chief Medical Officer
Alan Copperman
Chief Operating Officer
Peter Anevski
VP - Client Services
Lisa Greenbaum
VP - Marketing
Risa Fisher
Browse more venture capital transactions:
Prev: 5/3/2017: AltSchool venture capital transaction
Next: 5/3/2017: Bitfusion.io venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs